DGAP-News
Long-Time Novavax Board Member Jack Marsh Assumes Role of Director Emeritus
DGAP-News: Novavax, Inc. /
Long-Time Novavax Board Member Jack Marsh Assumes Role of Director
Emeritus
18.06.2014 / 22:52
---------------------------------------------------------------------
GAITHERSBURG, Md., 2014-06-18 22:52 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced that on June 12, 2014, the Honorable
John O. Marsh, Jr., resigned as a member of its Board of Directors. Mr. Marsh
joined the Board of Novavax in August 1991 and served as the company's interim
CEO and Chairman of the Board from 1996 to 1997. At various times during his 23
years as a Board member, he has served on all of the Board's various
committees. According to company records kept since 2005, Jack's attendance
rate at Board meetings was in excess of 90%; Mr. Marsh has attended every board
of directors meeting in person or by telephone since 2010. In recognition of
his 23 years of service, the Board of Directors has named Mr. Marsh Director
Emeritus.
A lifetime resident of Virginia, Mr. Marsh served in the U.S. Army during World
War II and continued with the Army Reserve and Army National Guard into the
1960s. A graduate of Washington and Lee University Law School, Mr. Marsh began
practicing law in 1952 in a variety of state and municipal roles. From 1963
until 1971 he served as a member of the U.S. House of Representatives. In 1973,
he was appointed Assistant Secretary of Defense, and in January 1974, became
the National Security Advisor for then Vice President Gerald Ford. He
subsequently became President Ford's cabinet-ranking Counsellor to the
President. In 1981, Mr. Marsh was appointed Secretary of the Army by President
Ronald Reagan where he served until 1989. Mr. Marsh has been awarded the
Department of Defense Distinguished Public Service Award on six occasions and
was awarded the Presidential Citizens Medal from President Reagan. Mr. Marsh
has been a Professor of Law and Ethics at various institutions including the
Virginia Military Institute, the College of William & Mary, and George Mason
University. He currently resides in Winchester, Virginia with his wife.
'Jack's legacy as a board member of Novavax cannot be underestimated. His
leadership at this company paved the way for our recent years of successful
vaccine development,' stated Stanley C. Erck, President and CEO. 'Jack's
enthusiasm for the company's business and his continued presence on the Board
through some very difficult early years has allowed Novavax to become a leading
recombinant vaccine development company and to make sustained progress in our
development of important recombinant vaccine candidates. I am delighted that
Jack has agreed to serve as a director emeritus to the Board where he can
continue to mentor and advise the other members of the Board, as well as our
senior management team.'
Chairman of the Board James F. Young, Ph.D. stated, 'I am honored and
privileged to have served on the Novavax Board of Directors with Jack Marsh.
Over the last four years, I have learned a great deal about the company's
history and about boardroom decision-making and diplomacy, witnessing Jack's
firm and confident presence in our boardroom. I am proud to call Jack a friend,
and I look forward to working with him in the future.'
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines and vaccine adjuvants to address a broad range of infectious
diseases worldwide. Using innovative proprietary recombinant nanoparticle
vaccine technology, the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
18.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
ISIN: US6700021040
End of News DGAP News-Service
---------------------------------------------------------------------
274357 18.06.2014
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced that on June 12, 2014, the Honorable
John O. Marsh, Jr., resigned as a member of its Board of Directors. Mr. Marsh
joined the Board of Novavax in August 1991 and served as the company's interim
CEO and Chairman of the Board from 1996 to 1997. At various times during his 23
years as a Board member, he has served on all of the Board's various
committees. According to company records kept since 2005, Jack's attendance
rate at Board meetings was in excess of 90%; Mr. Marsh has attended every board
of directors meeting in person or by telephone since 2010. In recognition of
his 23 years of service, the Board of Directors has named Mr. Marsh Director
Emeritus.
A lifetime resident of Virginia, Mr. Marsh served in the U.S. Army during World
War II and continued with the Army Reserve and Army National Guard into the
1960s. A graduate of Washington and Lee University Law School, Mr. Marsh began
practicing law in 1952 in a variety of state and municipal roles. From 1963
until 1971 he served as a member of the U.S. House of Representatives. In 1973,
he was appointed Assistant Secretary of Defense, and in January 1974, became
the National Security Advisor for then Vice President Gerald Ford. He
subsequently became President Ford's cabinet-ranking Counsellor to the
President. In 1981, Mr. Marsh was appointed Secretary of the Army by President
Ronald Reagan where he served until 1989. Mr. Marsh has been awarded the
Department of Defense Distinguished Public Service Award on six occasions and
was awarded the Presidential Citizens Medal from President Reagan. Mr. Marsh
has been a Professor of Law and Ethics at various institutions including the
Virginia Military Institute, the College of William & Mary, and George Mason
University. He currently resides in Winchester, Virginia with his wife.
'Jack's legacy as a board member of Novavax cannot be underestimated. His
leadership at this company paved the way for our recent years of successful
vaccine development,' stated Stanley C. Erck, President and CEO. 'Jack's
enthusiasm for the company's business and his continued presence on the Board
through some very difficult early years has allowed Novavax to become a leading
recombinant vaccine development company and to make sustained progress in our
development of important recombinant vaccine candidates. I am delighted that
Jack has agreed to serve as a director emeritus to the Board where he can
continue to mentor and advise the other members of the Board, as well as our
senior management team.'
Chairman of the Board James F. Young, Ph.D. stated, 'I am honored and
privileged to have served on the Novavax Board of Directors with Jack Marsh.
Over the last four years, I have learned a great deal about the company's
history and about boardroom decision-making and diplomacy, witnessing Jack's
firm and confident presence in our boardroom. I am proud to call Jack a friend,
and I look forward to working with him in the future.'
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines and vaccine adjuvants to address a broad range of infectious
diseases worldwide. Using innovative proprietary recombinant nanoparticle
vaccine technology, the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
18.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
ISIN: US6700021040
End of News DGAP News-Service
---------------------------------------------------------------------
274357 18.06.2014
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte